REFERENCES
1. Oh JH, Jun DW. The latest global burden of liver cancer: A past and present threat. Clin Mol Hepatol. 2023;29:355-7.
2. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-63.
3. Vo Quang E, Shimakawa Y, Nahon P. Epidemiological projections of viral-induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination. Liver Int. 2021;41:915-27.
4. Luo X, Lu Y, Zhang Y, et al. USP32 facilitates tumor development and is correlated with poor clinical outcomes in hepatocellular carcinoma patients and is modulated by the E2F7/miR-218-5p axis. LabMed Discovery. 2025;2:100102.
5. Kumar MA, Baba SK, Sadida HQ, et al. Extracellular vesicles as tools and targets in therapy for diseases. Signal Transduct Target Ther. 2024;9:27.
6. Marar C, Starich B, Wirtz D. Extracellular vesicles in immunomodulation and tumor progression. Nat Immunol. 2021;22:560-70.
7. Paskeh MDA, Entezari M, Mirzaei S, et al. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J Hematol Oncol. 2022;15:83.
8. Olejarz W, Dominiak A, Żołnierzak A, Kubiak-Tomaszewska G, Lorenc T. Tumor-Derived Exosomes in Immunosuppression and Immunotherapy. J Immunol Res. 2020;2020:6272498.
9. Morrissey SM, Zhang F, Ding C, et al. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metab. 2021;33:2040-58.e10.
10. Guan L, Wu B, Li T, et al. HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8(+) T-cell infiltration into tumors. Nat Commun. 2022;13:4078.
11. Gao J, Li S, Xu Q, et al. Exosomes Promote Pre-Metastatic Niche Formation in Gastric Cancer. Front Oncol. 2021;11:652378.
12. Komarova EY, Suezov RV, Nikotina AD, et al. Hsp70-containing extracellular vesicles are capable of activating of adaptive immunity in models of mouse melanoma and colon carcinoma. Sci Rep. 2021;11:21314.
13. Hopf M, Göhring W, Kohfeldt E, Yamada Y, Timpl R. Recombinant domain IV of perlecan binds to nidogens, laminin-nidogen complex, fibronectin, fibulin-2 and heparin. Eur J Biochem. 1999;259:917-25.
14. Urooj T, Wasim B, Mushtaq S, et al. Increased NID1 expression among breast cancer lung metastatic women; a comparative analysis between naive and treated cases. Recent Pat Anticancer Drug Discov. 2020;15:59-69.
15. Zhang B, Xu C, Liu J, Yang J, Gao Q, Ye F. Nidogen-1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients. Aging. 2021;13:9085-107.
16. Xue T, Yeung CLS, Mao X, et al. Development of a broadly potent neutralizing antibody targeting Nidogen 1 effectively inhibits cancer growth and metastasis in preclinical tumor models. J Transl Int Med. 2025;13:78-92.
17. Alečković M, Wei Y, LeRoy G, et al. Identification of Nidogen 1 as a lung metastasis protein through secretome analysis. Genes Dev. 2017;31:1439-55.
18. Rokavec M, Jaeckel S, Hermeking H. Nidogen-1/NID1 function and regulation during progression and metastasis of colorectal cancer. Cancers. 2023;15:5316.
19. Mao X, Tey SK, Yeung CLS, et al. Nidogen 1-enriched extracellular vesicles facilitate extrahepatic metastasis of liver cancer by activating pulmonary fibroblasts to secrete tumor necrosis factor receptor 1. Adv Sci. 2020;7:2002157.
20. Xue W, Kitzing T, Roessler S, et al. A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A. 2012;109:8212-7.
21. Moon CY, Belabed M, Park MD, Mattiuz R, Puleston D, Merad M. Dendritic cell maturation in cancer. Nat Rev Cancer. 2025;25:225-48.
22. Del Prete A, Salvi V, Soriani A, et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol. 2023;20:432-47.
23. Upadhaya P, Lamenza FF, Shrestha S, et al. Berry extracts and their bioactive compounds mitigate LPS and DNFB-mediated dendritic cell activation and induction of antigen specific T-Cell effector responses. Antioxidants. 2023;12:1667.
24. Plebanek MP, Xue Y, Nguyen YV, et al. A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression. Sci Immunol. 2024;9:eadi4191.
25. Maier B, Leader AM, Chen ST, et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature. 2020;580:257-62.
26. Zheng M, Yu J, Tian Z. Characterization of the liver-draining lymph nodes in mice and their role in mounting regional immunity to HBV. Cell Mol Immunol. 2013;10:143-50.
27. Li H, Chiang CL, Kwak KJ, et al. Extracellular vesicular analysis of glypican 1 mRNA and protein for pancreatic cancer diagnosis and prognosis. Adv Sci. 2024;11:e2306373.
28. Heidegger S, Stritzke F, Dahl S, et al. Targeting nucleic acid sensors in tumor cells to reprogram biogenesis and RNA cargo of extracellular vesicles for T cell-mediated cancer immunotherapy. Cell Rep Med. 2023;4:101171.
29. Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560:382-6.
30. Ricklefs FL, Alayo Q, Krenzlin H, et al. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv. 2018;4:eaar2766.
31. Wang X, Yang X, Huang C, et al. Tumor-derived extracellular vesicle PD-1 promotes tumor immune evasion via disruption of peripheral T cell homeostasis. Cancer Lett. 2025;612:217486.
32. Théry C, Duban L, Segura E, Véron P, Lantz O, et al. Indirect activation of naïve CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol. 2002;3:1156-62.
33. Salimu J, Webber J, Gurney M, Al-Taei S, Clayton A, Tabi Z. Dominant immunosuppression of dendritic cell function by prostate-cancer-derived exosomes. J Extracell Vesicles. 2017;6:1368823.
35. Jagroop R, Martin CJ, Moorehead RA. Nidogen 1 regulates proliferation and migration/invasion in murine claudin-low mammary tumor cells. Oncol Lett. 2021;21:52.
36. Alshoubaki YK, Nayer B, Lu YZ, et al. Tregs delivered post-myocardial infarction adopt an injury-specific phenotype promoting cardiac repair via macrophages in mice. Nat Commun. 2024;15:6480.
37. Zbinden A, Layland SL, Urbanczyk M, et al. Nidogen-1 mitigates ischemia and promotes tissue survival and regeneration. Adv Sci. 2021;8:2002500.
38. Caracuel-Peramos R, Rodríguez-Baena FJ, Redondo-García S, et al. Loss of the extracellular protease ADAMTS1 reveals an antitumorigenic program involving the action of NIDOGEN-1 on macrophage polarization. Oncoimmunology. 2025;14:2508057.
39. Sage J, Leblanc-Noblesse E, Nizard C, et al. Cleavage of nidogen-1 by cathepsin S impairs its binding to basement membrane partners. PLoS One. 2012;7:e43494.
40. Mayer U, Mann K, Timpl R, Murphy G. Sites of nidogen cleavage by proteases involved in tissue homeostasis and remodelling. Eur J Biochem. 1993;217:877-84.
41. Dionisi M, De Archangelis C, Battisti F, et al. Tumor-derived microvesicles enhance cross-processing ability of clinical grade dendritic cells. Front Immunol. 2018;9:2481.
42. Rughetti A, Rahimi H, Belleudi F, et al. Microvesicle cargo of tumor-associated MUC1 to dendritic cells allows cross-presentation and specific carbohydrate processing. Cancer Immunol Res. 2014;2:177-86.
43. Zhang H, Tang K, Zhang Y, et al. Cell-free tumor microparticle vaccines stimulate dendritic cells via cGAS/STING signaling. Cancer Immunol Res. 2015;3:196-205.
45. Fan Z, Wu C, Chen M, et al. The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation. Acta Pharm Sin B. 2022;12:1041-53.
46. Thumkeo D, Punyawatthananukool S, Prasongtanakij S, et al. PGE2-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment. Cell Rep. 2022;39:110914.
47. Yeung CLS, Cui L, Wang J, et al. Small extracellular vesicle-derived nidogen 1 promotes HCC carcinogenesis via transglutaminase 3-mediated YAP/TAZ signaling. J Extracell Vesicles. 2026;15:e70359.
48. Chen S, Huang X, Xue Y, et al. Nanotechnology-based mRNA vaccines. Nat Rev Methods Primers. 2023;3:63.
